ACOG Guidance on Cell-Free DNA/NIPT Testing for IVF Pregnancies
The specific ACOG article you're looking for is ACOG Committee Opinion No. 640 "Cell-Free DNA Screening For Fetal Aneuploidy" (2015), published in Obstetrics and Gynecology, which provides guidance on cfDNA/NIPT testing that applies to all pregnancies including those conceived via IVF. 1
Key ACOG Publications on cfDNA/NIPT
The primary ACOG guidance documents addressing cell-free DNA screening include:
Committee Opinion No. 640 (2015) - This is the main ACOG statement on cell-free DNA screening for fetal aneuploidy that replaced the earlier Committee Opinion No. 545 from 2012 1, 2
SMFM Consult Series #36 (2015) published in the American Journal of Obstetrics and Gynecology - This comprehensive document provides detailed guidance on prenatal aneuploidy screening using cell-free DNA, including technical aspects, clinical applications, and counseling considerations 3
ACOG's Position on cfDNA Testing (Applicable to IVF Pregnancies)
General Recommendations
ACOG states that all pregnant women should be offered aneuploidy screening or diagnostic testing regardless of maternal age, with options including first-trimester screening, cell-free DNA screening, or diagnostic testing with CVS or amniocentesis 4, 5
Cell-free DNA screening has high sensitivity and specificity for trisomy 18 and trisomy 21, regardless of which molecular technique is used 1
Important Limitations Emphasized by ACOG
cfDNA screening does not replace diagnostic tests such as chorionic villus sampling or amniocentesis and is limited in its ability to identify all chromosome abnormalities 1
Management decisions, including termination of pregnancy, should not be based on cfDNA screening results alone - diagnostic confirmation is required for all positive results 1
Cell-free DNA screening does not assess risk of fetal anomalies such as neural tube defects or ventral wall defects 1
A negative cfDNA test result does not ensure an unaffected pregnancy 1
Special Considerations for IVF Pregnancies
Recent Evidence on IVF/PGT-A Pregnancies
Recent data demonstrates that prenatal cfDNA screening after single euploid embryo transfer (following PGT-A) shows high concordance with preimplantation genetic testing results 6
The positive predictive value for an abnormal prenatal cfDNA screening result after euploid embryo transfer is reassuringly low at 7.7%, compared to 38% in pregnancies from untested embryos 6
Fetal fraction in singleton pregnancies after PGT-A tested embryos is not different from pregnancies with untested embryos (9.5% ± 4% vs. 10.3% ± 4%), indicating cfDNA screening performs equally well in both populations 6
Clinical Algorithm for IVF Pregnancies
For IVF pregnancies after euploid embryo transfer: Patients can reliably undergo prenatal cfDNA screening during the first trimester, with the understanding that positive results have a low positive predictive value and require diagnostic confirmation 6
For IVF pregnancies from untested embryos: Standard cfDNA screening recommendations apply, with higher positive predictive values similar to spontaneous conceptions 6
Timing: cfDNA screening can be performed after 10 weeks of gestation when approximately 10-15% of total cfDNA in maternal plasma is of placental origin 3
Critical Counseling Points
Patients must understand that cfDNA is a screening test, not a diagnostic test, despite its high sensitivity (99%) and specificity for trisomy 21 7
All positive cfDNA results require diagnostic confirmation with either CVS or amniocentesis before making definitive pregnancy decisions 7, 1
Women with "no call" or indeterminate results from cfDNA screening should receive further genetic counseling and be offered comprehensive ultrasound evaluation and diagnostic testing because of an increased risk of aneuploidy 1